Identification and Verification of Translational Biomarkers for Patient Stratification and Precision Medicine
|
|
- Emory Shelton
- 5 years ago
- Views:
Transcription
1 Biomarkers for Patients Stratification and Precision Medicine -- Cancer and Beyond AAPS National Biotechnology Conference, Boston on May 16-18, 2016 Identification and Verification of Translational Biomarkers for Patient Stratification and Precision Medicine Bin Li, PhD, Associate Director Translational Medicine Takeda Pharmaceuticals International Co. May 18, 2016
2 Disclaimer Any views or opinions presented here are solely those of the author and do not necessarily represent those of the company.
3 Outline Design and implement a predictive modeling framework Method evaluation Using SOC drugs to evaluate the predictive modeling approach Build Erlotinib and Sorafenib sensitivity models using cell line data Tested the models using real patients output (PFS from BATTLE trials) Predict potential drug target cancer indications Method comparison on NCI-DREAM challenge A fair comparison on predictive modeling methods, used by 47 teams on 22 drugs
4 What we want to achieve on the predictive models Goal: To discover patient selection biomarkers using preclinical data, e.g. using cell line viability screens We want to be testing hypothesis in Ph II and using Ph III clinical trials to select the right patients for treatment What we want to gain from building the predictive models Build a predictive model on cell line data, which can be used for patients Model derived signature genes reflects a drug s MOA Each drug s predictive model should be drug specific Using the predictive model for cancer indication selection
5 Design and development of a PLSR based predictive modeling framework Learned from FDA organized MAQC_II observations Nat. Biotech. 2010, 28, academic and industry teams participated Most of the state-of-art computational approaches were applied We decided to build our modeling framework based partial least squares regression (PLSR) method Technique considerations on choosing PLSR method: PLSR is similar to PCA, while it could be more effective than PCA since it targets best X-Y relationship (PCA captures key variance in X only) PLSR is well known as a dimension reduction tool (ideal for genomic data) PLSR was designed to address multicollinearity issue Learned from CCLE and Sanger observations Nature, 2012, 483, 603; Nature, 2012, 483, 570 Both teams adopted Elastic Net (EN) method for biomarker discovery, while EN approach is very similar to PLSR (EN seeks max coefficient vs PLSR seeks max covariance)
6 A specially designed modeling framework to capture consensus information from the dataset (A) Input data: GEP & IC50 (B) Panel cell lines Training a model on cell line data Data reduction Feature selection Model training using a specially designed splitting strategy Obtain a core model (C) 42% random.training 28% random.validation 30% balance.validation (10-fold cross validation) Random.validation Sub-testing AUC vs. cor Correlation Correlation Balance.validation Sep-testing AUC vs. cor Get a pathway based core model (D) AUC AUC Testing the model on patients data Test model Bin Li, Hyunjin Shin, et al. PLoS ONE 2015, 10(6): e
7 Pathway-based signature genes network reconstruction
8 Outline Design and implement a predictive modeling framework Method evaluation Using SOC drugs to evaluate the predictive modeling approach Build Erlotinib and Sorafenib sensitivity models using cell line data Tested the models using real patients output (PFS from BATTLE trials) Predict potential drug target cancer indications Method comparison on NCI-DREAM challenge A fair comparison on predictive modeling methods, used by 47 teams on 22 drugs
9 Trained the Erlotinib PLSR model on cell line data: Built a good model with 77-91% accuracy Ricerca Oncopanel cell based assay: Re-predicting Ricerca log2(ic50) Prostate Pancreas Lung Liver Skin Kidney Head_and_Neck not_classified Soft_Tissue Haematopoietic_a nd_lymphoid Bladder Breast CNS Colon Colon_GI Endocrine Female_GU_Cervi x Female_GU_other Ricerca Screen: cell lines - varying histological origin -10 point dose titration => IC50s - Baseline Microarray data Accuracy estimation: Upper boundary: 91% Lower boundary: 77%
10 Overall work flow on model building and testing: on Erlotinib case study Training a model on cell line data Testing the model on patients data Input data: GEP & IC50 Data reduction Feature selection Model training using a specially designed splitting strategy Obtain a core model Get a pathway based core model Test model probesets 3787 probesets 485 genes (full model) 187 core genes (core model) 51 genes (final pathway model)
11 Signature genes reflect known MOA of Erlotinib and Sorafenib (A) Erlotinib (B) Sorafenib
12 Test the Erlotinib model using BATTLE clinic trial: background Trained a PLSR model using Erlotinib Ricerca screen data (IC50s) On Affymetrix U133plus; 240 cell lines on multiple cancer types Using the model to predict patients survival (PFS) in BATTLE clinic trial On Affymetrix Hu Gene 1.0 ST; 25 Erlotinib patients on NSCLC
13 Cell line derived drug sensitivity models were able to predict patients responses and are drug specific (A) E_model pred E_PFS (B) S_model pred S_PFS Proportion of Cases P = 0.09 HR = 0.43 Proportion of Cases P = HR = Monthes from Start of Therapy Monthes from Start of Therapy (C) E_model pred S_PFS (D) S_model pred E_PFS Proportion of Cases P = 0.32 HR = 1.87 Proportion of Cases P = 0.54 HR = Monthes from Start of Therapy Monthes from Start of Therapy E: Erlotinib; S: Sorafenib; red: marker pos; green: marker neg
14 Using the predictive models for drug target cancer indication selection: build a translational medicine data warehouse To provide a large, well organized, and integrated dataset Compound screen data, public data, and clinic outputs Standardize vocabulary and Normalize experimental results Use standard terminology for the same concepts, e.g. gender, sex Global normalization on gene expression data Current data in Vahalla Takeda proprietary data: VELCADE clinical trials; cancer cell line screen data on multiple Takeda Oncology compounds Public data: > 2000 GEO studies, with ~ 350 GEO studies manually curated; TCGA data; CCLE and Sanger cancer cell line panel data A R-interface for computational scientists to build/test predictive models
15 Predicting Erlotinib or Sorafenib sensitive percentage of samples to select drug target cancer indications Cancer Type # of samples Pred. Erlotinib Sen. percentage Pred. Sorafenib Sen. percentage FDA approved Erlotinib or Sorafenib indications: Lung Cancer Liver Cancer Kidney Cancer Some interesting indications predicted to be sensitive to Erlotinib or Sorafenib: Head and Neck Cancer Bladder Cancer Haematopoietic Neoplasms Bone Cancer Breast Cancer Colorectal Cancer Pancreatic Cancer Erlotinib was approved in Lung cancer Sorafenib was approved in Live and Kidney cancers Erlotinib failed in one Kidney cancer PIII clinical trial Predicted additional Erlotinib sensitive cancer indications Predicted additional Sorafenib sensitive cancer indications Bin Li, Hyunjin Shin, et al. PLoS ONE 2015, 10(6): e
16 What we want to achieve on the predictive models Goal: To discover patient selection biomarkers using preclinical data, e.g. using cell line viability screens We want to be testing hypothesis in Ph II and using Ph III clinical trials to select the right patients for treatment What we want to gain from building the predictive models Build a predictive model on cell line data, which can be used for patients Model derived signature genes reflects a drug s MOA Each drug s predictive model should be drug specific Using the predictive model for cancer indication selection
17 Outline Design and implement a predictive modeling framework Method evaluation Using SOC drugs to evaluate the predictive modeling approach Build Erlotinib and Sorafenib sensitivity models using cell line data Tested the models using real patients output (PFS from BATTLE trials) Predict potential drug target cancer indications Method comparison on NCI-DREAM challenge A fair comparison on predictive modeling methods, used by 47 teams on 22 drugs
18 NCI-DREAM consortium testing drug sensitivity predictive models: 47 teams and 31 drugs The NCI-DREAM training, testing, and scoring (Nat. Biotech. 2014, 32, ): Official Results (Nat. Biotech) TMed comp bio team excluded 9 drugs with flat IC50 distributions: Follow-up analysis (internal)
19 TBOS team offically ranked No. 10 among 44 teams (while we only predicted 22 out of 31 drugs) For Official analysis on 31 drugs: TBOS team ranks No. 10 TBOS team teamfin Team_475 Team_690 Team_511 Team_680 Team_425 Team_603 TMM1_GEP Team_689 Team_691 Team_176 Team_418 Team_474 Team_545 For the 22 drugs we built predictive models: TBOS team ranks No. 3 on summarized scores and No. 1 on median scores
20 Conclusions: We designed and implemented a predictive modeling framework The predictive modeling approach was validated on Erlotinib/Sorafenib Cell line data derived models can predict patients response Model derived signature genes could reflect each drug s MOA Predictive models are drug specific The models were also able to predict potential drug target cancer indications Method comparison on NCI-DREAM challenge Our biomarker method was highly competitive among 47 teams on 22 drugs
21 Acknowledgements TMed project leaders Yuko Ishii Bill Trepicchio Steve Blakemore George Mulligan Andy Dorner TMed computational team Gene Shin Andrew Krueger Dave Merberg Lei Shen TMed assay team Sunita Badola Scott Verrow Elena Izmailova Thomas Reuters Olga Pustovalova Georgy Gulbekyan Marina Bessarabova
Translational Bioinformatics: Connecting Genes with Drugs
Translational Bioinformatics: Connecting Genes with Drugs Aik Choon Tan, Ph.D. Associate Professor of Bioinformatics Division of Medical Oncology Department of Medicine aikchoon.tan@ucdenver.edu 11/14/2017
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationHealth Systems Adoption of Personalized Medicine: Promise and Obstacles. Scott Ramsey Fred Hutchinson Cancer Research Center Seattle, WA
Health Systems Adoption of Personalized Medicine: Promise and Obstacles Scott Ramsey Fred Hutchinson Cancer Research Center Seattle, WA Cancer Pharmaceutical Pricing Bach P. NEJM 2009;360:626 Opportunities
More informationDeSigN: connecting gene expression with therapeutics for drug repurposing and development. Bernard lee GIW 2016, Shanghai 8 October 2016
DeSigN: connecting gene expression with therapeutics for drug repurposing and development Bernard lee GIW 2016, Shanghai 8 October 2016 1 Motivation Average cost: USD 1.8 to 2.6 billion ~2% Attrition rate
More informationOncology Drug Development Using Molecular Pathology
Oncology Drug Development Using Molecular Pathology Introduction PRESENTERS Lee Schacter, PhD, MD, FACP Executive Medical Director, Oncology Clinipace Worldwide Martha Bonino Director, Strategic Accounts
More informationNCI Precision Medicine Trial Designs
NCI Precision Medicine Trial Designs Shakun Malik, M.D. Head, Thoracic and Head & Neck Cancer Therapeutics Cancer Therapy Evaluation Program (CTEP) National Cancer institute/nih 1 Outline Background Current
More informationNation nal Cancer Institute. Prevalence Projections: The US Experience
Nation nal Cancer Institute Prevalence Projections: The US Experience State of Art Methods for the Analysis of Population- Based Cancer Data January 22-23, 2014 Ispra, Italy U.S. DEPARTMENT OF HEALTH AND
More informationmicrorna-guided diagnostics for neuroendocrine tumors
microrna-guided diagnostics for neuroendocrine tumors Neil Renwick Dept Pathology and Molecular Medicine Queen s University SEAMO Research and Innovation Showcase Isabel Bader Centre for the Performing
More informationCDC & Florida DOH Attribution
FCDS Annual Educational Conference Tampa, Florida July 19, 2018 Steven Peace, CTR 1 CDC & Florida DOH Attribution Funding for this conference was made possible (in part) by the Centers for Disease Control
More informationCase Studies on High Throughput Gene Expression Data Kun Huang, PhD Raghu Machiraju, PhD
Case Studies on High Throughput Gene Expression Data Kun Huang, PhD Raghu Machiraju, PhD Department of Biomedical Informatics Department of Computer Science and Engineering The Ohio State University Review
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationData Harmonization Efforts Across the Cancer Staging System. Donna M. Gress, RHIT, CTR AJCC Technical Specialist
Data Harmonization Efforts Across the Cancer Staging System Donna M. Gress, RHIT, CTR AJCC Technical Specialist Objectives Describe efforts underway to harmonize data elements and concepts used in cancer
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationUniversity of Pittsburgh Cancer Institute UPMC CancerCenter. Uma Chandran, MSIS, PhD /21/13
University of Pittsburgh Cancer Institute UPMC CancerCenter Uma Chandran, MSIS, PhD chandran@pitt.edu 412-648-9326 2/21/13 University of Pittsburgh Cancer Institute Founded in 1985 Director Nancy Davidson,
More informationPersonalized Therapy for Prostate Cancer due to Genetic Testings
Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center
More informationCDC & Florida DOH Attribution
SCCRA/GATRA Regional Conference North Charleston, SC 11/6/2018 Steven Peace, CTR 1 CDC & Florida DOH Attribution Funding for this conference was made possible (in part) by the Centers for Disease Control
More informationPotential Opportunities for Collaboration with Pancreatic U01s
Potential Opportunities for Collaboration with Pancreatic U01s Sudhir Srivastava, PhD, MPH Chief, Cancer Biomarkers Research Group Division of Cancer Prevention Background Recalcitrant Cancer Research
More informationMEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site
POLICY: PG0364 ORIGINAL EFFECTIVE: 04/22/16 LAST REVIEW: 07/26/18 MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site GUIDELINES This policy does not certify benefits or authorization
More informationOHSU Knight Cancer Institute Overview and Update
OHSU Knight Cancer Institute Overview and Update for Senate Health Care and Human Services Committee Steve Stadum, COO, OHSU Knight Cancer Institute September 15, 2014 Presentation Brief Overview of OHSU
More informationDiscovering Meaningful Cut-points to Predict High HbA1c Variation
Proceedings of the 7th INFORMS Workshop on Data Mining and Health Informatics (DM-HI 202) H. Yang, D. Zeng, O. E. Kundakcioglu, eds. Discovering Meaningful Cut-points to Predict High HbAc Variation Si-Chi
More informationKidney Cancer Diagnostic Kit
Kidney Cancer Diagnostic Kit Multiplex Human Renal Cell carcinoma Biomarker Test Kit ELISA kit for Human Renal Cell Carcinoma A simple antibody-based blood test designed to detect kidney cancer a Non-invasive,
More informationUsing CART to Mine SELDI ProteinChip Data for Biomarkers and Disease Stratification
Using CART to Mine SELDI ProteinChip Data for Biomarkers and Disease Stratification Kenna Mawk, D.V.M. Informatics Product Manager Ciphergen Biosystems, Inc. Outline Introduction to ProteinChip Technology
More informationPanel One: Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics
Panel One: Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics Alternative Trial Designs Based on Tumor Genetics and/or Pathway Characteristics Instead of Histology George D. Demetri,
More informationAccelerating Translation at Dana-Farber Cancer Institute*
Accelerating Translation at Dana-Farber Cancer Institute* *and our partner institutions February 12, 2013 Edward J Benz JR, MD Dana Farber Cancer Institute 1 2 Academic Structure All Dana-Farber faculty
More informationBiomarker as essential part of clinical development. PhUSE 2014, London, Renuka Chinthapally, Cytel
Biomarker as essential part of clinical development PhUSE 2014, London, Renuka Chinthapally, Cytel 1 Disclaimer Any comments or statements made here are solely those of the author and do not necessarily
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationPhysician On-line Staging Application. Darlene Dale Head, PMH Cancer Registry
Physician On-line Staging Application Darlene Dale Head, PMH Cancer Registry NAACCR 2004 Outline Overview of Princess Margaret Hospital History of Staging at PMH Steps to On-Line Physician Staging at PMH
More informationAccelerate Your Research with Conversant Bio
Imagination has given us the steam engine, the telephone, the talkingmachine and the automobile, for these things had to be dreamed of before they became realities. So I believe that dreams... are likely
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationNGS ONCOPANELS: FDA S PERSPECTIVE
NGS ONCOPANELS: FDA S PERSPECTIVE CBA Workshop: Biomarker and Application in Drug Development August 11, 2018 Rockville, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration
More informationReview on Tumour Doubling Time (DT) To review the studies that measuring the actual tumour doubling time for human cancers.
Review on Tumour Doubling Time (DT) Objective To review the studies that measuring the actual tumour doubling time for human cancers. Methods We searched the Medline database from January 1966 to January
More informationone patient advocacy group (Myeloma Canada) the submitter (Cancer Care Ontario Hematology Disease Site Group) the manufacturer (Janssen Inc.
perc noted that the pcodr Economic Guidance Panel s estimates of the use of bortezomib in both pre- ASCT and post-asct settings when compared with standard induction therapy and observation-only maintenance
More informationModule 3: Pathway and Drug Development
Module 3: Pathway and Drug Development Table of Contents 1.1 Getting Started... 6 1.2 Identifying a Dasatinib sensitive cancer signature... 7 1.2.1 Identifying and validating a Dasatinib Signature... 7
More informationNGS IN ONCOLOGY: FDA S PERSPECTIVE
NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for
More informationNCI Community Cancer Centers Program
NCI Community Cancer Centers Program BIOSPECIMENS SURVIVORSHIP Andrew L. Salner, MD FACR Director, Helen & Harry Gray Cancer Center Hartford Hospital Hartford, CT Hartford Hospital 865 bed community and
More informationHow to address tumour heterogeneity in next generation oncology trials
How to address tumour heterogeneity in next generation oncology trials Cihangir YANDIM, PhD Research Associate in Cancer Therapeutics and Clinical Sciences Dr. Cihangir Yandim - CTIP 2016, Hamburg 1 Founded
More informationNEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650)
NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Kristin Reed (650) 467-9831 FDA APPROVES AVASTIN IN COMBINATION WITH CHEMOTHERAPY
More informationCancer survival by stage at diagnosis in Wales,
Cancer survival by stage at diagnosis in Wales, 2011-2014 Welsh Cancer Intelligence and Surveillance Unit www.wcisu.wales.nhs.uk Latest available one-year net cancer survival by stage at diagnosis official
More information(Regulatory) views on Biomarker defined Subgroups
(Regulatory) views on Biomarker defined Subgroups Norbert Benda Disclaimer: Views expressed in this presentation are the author's personal views and not necessarily the views of BfArM Biomarker defined
More informationAction to Cure Kidney Cancer Campaign to Fund Kidney Cancer Research
Action to Cure Kidney Cancer 2016 Campaign to Fund Kidney Cancer Research Kidney Cancer Facts 9 th most common cancer in the U.S. Until recently, 3 rd highest rate of increasing incidence of all cancers
More informationPanel: Machine Learning in Surgery and Cancer
Panel: Machine Learning in Surgery and Cancer Professor Dimitris Bertsimas, SM 87, PhD 88, Boeing Leaders for Global Operations Professor of Management; Professor of Operations Research; Co-Director, Operations
More informationLung Cancer Screening
Lung Cancer Screening v Lung Cancer: America s leading cancer killer Annual US cancer mortality 158,040 221,000 new diagnoses in US 4,100 14,180 27,540 Lung 40,560 40,730 49,700 Cervix Ovary Prostate Pancreas
More informationIdentification of Tissue Independent Cancer Driver Genes
Identification of Tissue Independent Cancer Driver Genes Alexandros Manolakos, Idoia Ochoa, Kartik Venkat Supervisor: Olivier Gevaert Abstract Identification of genomic patterns in tumors is an important
More informationBiomarkers in oncology drug development
Biomarkers in oncology drug development Andrew Stone Stone Biostatistics Ltd EFSPI Biomarkers and Subgroups June 2016 E: andrew@stonebiostatistics.com T: +44 (0) 7919 211836 W: stonebiostatistics.com available
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationMODELING AN SMT LINE TO IMPROVE THROUGHPUT
As originally published in the SMTA Proceedings MODELING AN SMT LINE TO IMPROVE THROUGHPUT Gregory Vance Rockwell Automation, Inc. Mayfield Heights, OH, USA gjvance@ra.rockwell.com Todd Vick Universal
More informationHeritability enrichment of differentially expressed genes. Hilary Finucane PGC Statistical Analysis Call January 26, 2016
Heritability enrichment of differentially expressed genes Hilary Finucane PGC Statistical Analysis Call January 26, 2016 1 Functional genomics + GWAS gives insight into disease relevant tissues Trynka
More informationPlans for the Precision Cancer Medicine Institute University of Oxford
Plans for the Precision Cancer Medicine Institute University of Oxford STFC & Particle Accelerators and Beams group workshop on particle accelerators for medicine 17 th February 2015 Claire Timlin The
More informationCase Studies in Bayesian Augmented Control Design. Nathan Enas Ji Lin Eli Lilly and Company
Case Studies in Bayesian Augmented Control Design Nathan Enas Ji Lin Eli Lilly and Company Outline Drivers for innovation in Phase II designs Case Study #1 Pancreatic cancer Study design Analysis Learning
More informationWhat EU research policy can do for conditions such as chronic pain?
The EU Framework Programme for Research and Innovation HORIZON 2020 What EU research policy can do for conditions such as chronic pain? K Berkouk, PhD Deputy Head of Unit, Non-communicable diseases and
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The National Surgical
More informationNCI Cancer Moonshot. Christine Siemon National Cancer Institute, NIH. November 30, 2017
NCI Cancer Moonshot Christine Siemon National Cancer Institute, NIH November 30, 2017 Presidential Memo 2016 Overall Goals of the Cancer Moonshot Accelerate progress in cancer, including prevention & screening
More informationMATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS
MATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS DR. RACHEL E. LAING*, OLIVIER LESUEUR*, STAN HOPKINS AND DR. SEAN X. HU MAY 2012 Recent advances in oncology, such
More informationFellow GU Lecture Series, Prostate Cancer. Asit Paul, MD, PhD 02/20/2018
Fellow GU Lecture Series, 2018 Prostate Cancer Asit Paul, MD, PhD 02/20/2018 Disease Burden Screening Risk assessment Treatment Global Burden of Prostate Cancer Prostate cancer ranked 13 th among cancer
More informationResearch For the Future. Len Lichtenfeld, MD, MACP Interim Chief Medical and Scientific Officer
Research For the Future Len Lichtenfeld, MD, MACP Interim Chief Medical and Scientific Officer 1 2 ATTACKING CANCER FROM EVERY ANGLE 3 CANCER PREVENTION STUDIES (CPS) Intramural Research Smoking Obesity
More informationMachine Learning to Inform Breast Cancer Post-Recovery Surveillance
Machine Learning to Inform Breast Cancer Post-Recovery Surveillance Final Project Report CS 229 Autumn 2017 Category: Life Sciences Maxwell Allman (mallman) Lin Fan (linfan) Jamie Kang (kangjh) 1 Introduction
More informationSUMMARY OF perc DELIBERATIONS ON REQUEST FOR ADVICE
SUMMARY OF perc DELIBERATIONS ON REQUEST FOR ADVICE On March 7, 2013, perc issued a reimbursement recommendation for axitinib (Inlyta) for metastatic RCC. On April 18, 2017, the pcodr PAG submitted a Request
More informationDeconRNASeq: A Statistical Framework for Deconvolution of Heterogeneous Tissue Samples Based on mrna-seq data
DeconRNASeq: A Statistical Framework for Deconvolution of Heterogeneous Tissue Samples Based on mrna-seq data Ting Gong, Joseph D. Szustakowski April 30, 2018 1 Introduction Heterogeneous tissues are frequently
More informationOncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
More informationTranslational Platform for the Development of Targeted Therapeutics
Translational Platform for the Development of Targeted Therapeutics Ondřej Kalous, MD Associate Project Scientist UCLA Translational Oncology Research Laboratories (TORL) Jonsson Comprehensive Cancer Center
More informationData Sharing Consortiums and Large Datasets to Inform Cancer Diagnosis
February, 13th 2018 Data Sharing Consortiums and Large Datasets to Inform Cancer Diagnosis Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging and Pathology Expertise and Technologies:
More informationCognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015 Cognitive Impairment Associated
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationCorporate Medical Policy
Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary
More informationSU2C TOP SCIENCE ACCOMPLISHMENTS
SU2C TOP SCIENCE ACCOMPLISHMENTS INTRODUCTION Since our founding in 2008, Stand Up To Cancer has funded 87 team science projects, with budgets ranging from $250,000 for a short research project to over
More informationPHASE 1 CLINICAL TRIALS: DESIGNS AND CONSIDERATIONS. Sarit Assouline, MD, MSc, FRCPC Associate professor, McGill University Jewish General Hospital
PHASE 1 CLINICAL TRIALS: DESIGNS AND CONSIDERATIONS Sarit Assouline, MD, MSc, FRCPC Associate professor, McGill University Jewish General Hospital Outline Introduction Goal of Phase I studies in oncology
More informationWORKING P A P E R. Comparative Performance of the MS-DRGS and RDRGS in Explaining Variation in Cost for Medicare Hospital Discharges BARBARA O.
WORKING P A P E R Comparative Performance of the MS-DRGS and RDRGS in Explaining Variation in Cost for Medicare Hospital Discharges BARBARA O. WYNN WR-606 This product is part of the RAND Health working
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationPredicting Kidney Cancer Survival from Genomic Data
Predicting Kidney Cancer Survival from Genomic Data Christopher Sauer, Rishi Bedi, Duc Nguyen, Benedikt Bünz Abstract Cancers are on par with heart disease as the leading cause for mortality in the United
More informationAccepted Manuscript. Pancreatic Cancer Subtypes: Beyond Lumping and Splitting. Andrew J. Aguirre
Accepted Manuscript Pancreatic Cancer Subtypes: Beyond Lumping and Splitting Andrew J. Aguirre PII: S0016-5085(18)35213-2 DOI: https://doi.org/10.1053/j.gastro.2018.11.004 Reference: YGAST 62235 To appear
More informationLecture Outline Biost 517 Applied Biostatistics I. Statistical Goals of Studies Role of Statistical Inference
Lecture Outline Biost 517 Applied Biostatistics I Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics University of Washington Statistical Inference Role of Statistical Inference Hierarchy of Experimental
More informationLecture Outline Biost 517 Applied Biostatistics I
Lecture Outline Biost 517 Applied Biostatistics I Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics University of Washington Lecture 2: Statistical Classification of Scientific Questions Types of
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationMyriad Genetics mychoice HRD Update 06/30/2016
Myriad Genetics mychoice HRD Update 06/30/2016 1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationBowel Disease Research Foundation
Research Project Annual Report Lead investigator Dr Ricky Sharma Institution Department of Oncology, University of Oxford Project Title Making radiotherapy for rectal cancer more effective by identifying
More informationGene-microRNA network module analysis for ovarian cancer
Gene-microRNA network module analysis for ovarian cancer Shuqin Zhang School of Mathematical Sciences Fudan University Oct. 4, 2016 Outline Introduction Materials and Methods Results Conclusions Introduction
More informationMyriad Genetics Corporate Presentation 6/4/13
Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationFrom single studies to an EBM based assessment some central issues
From single studies to an EBM based assessment some central issues Doug Altman Centre for Statistics in Medicine, Oxford, UK Prognosis Prognosis commonly relates to the probability or risk of an individual
More informationClinical Trials in Prostate Cancer: To do or not To Do?
Clinical Trials in Prostate Cancer: To do or not To Do? Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Associate Director for Diversity Programs Sidney Kimmel Cancer
More informationSupplementary Figures
Supplementary Figures Supplementary Figure 1. Pan-cancer analysis of global and local DNA methylation variation a) Variations in global DNA methylation are shown as measured by averaging the genome-wide
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationThe Intermountain Oncology Clinical Program: Present and Future
The Intermountain Oncology Clinical Program: Present and Future William T. Sause, MD Director of Radiation Oncology; Intermountain Healthcare; Murray, Utah Objectives: Define current status of the Cancer
More informationEpidemiology of weak associations The case of nutrition and cancer. Paolo Boffetta Icahn School of Medicine at Mount Sinai New York NY
Epidemiology of weak associations The case of nutrition and cancer Paolo Boffetta Icahn School of Medicine at Mount Sinai New York NY Causality in epidemiology Epidemiology can lead to the identification
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationModeling & Simulation to support evaluation of Safety and Efficacy of Drugs in Older Patients
Modeling & Simulation to support evaluation of Safety and Efficacy of Drugs in Older Patients Eva Bredberg, Director Global Clinical Pharmacology, AstraZeneca On behalf of EFPIA EMA Geriatrics Workshop
More informationSeptember 30, Eric BASTINGS, MD. Acting Director Division of Neurology Products (DNP) Center for Drug Evaluation and Research (CDER)
ISCTM Autumn Conference Options and methods to improve cognitive assessment in clinical trials of AD and its precursors September 30, 2013 Eric BASTINGS, MD Acting Director Division of Neurology Products
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland October 2012 First published in June 2004, revised with each National Statistics publication Next due for revision April 2013 Information Services Division NHS National Services Scotland
More informationEvaluation of Record Linkage for SEER breast cancer registries to Oncotype DX tests
Evaluation of Record Linkage for SEER breast cancer registries to Oncotype DX tests Michael D. Larsen, Will Howe, Nicola Schussler, Benmei Liu, Valentina Petkov, Mandi Yu FCSM Research Conference2015,
More informationINTERIM MANAGEMENT STATEMENT Q3 2017
INTERIM MANAGEMENT STATEMENT Q3 2017 Significant progress across all clinical programs New pre-clinical immunooncology data to be presented during R&D Day in New York Research & Development highlights:
More informationNew Enhancements: GWAS Workflows with SVS
New Enhancements: GWAS Workflows with SVS August 9 th, 2017 Gabe Rudy VP Product & Engineering 20 most promising Biotech Technology Providers Top 10 Analytics Solution Providers Hype Cycle for Life sciences
More informationKnowledge Discovery and Data Mining. Testing. Performance Measures. Notes. Lecture 15 - ROC, AUC & Lift. Tom Kelsey. Notes
Knowledge Discovery and Data Mining Lecture 15 - ROC, AUC & Lift Tom Kelsey School of Computer Science University of St Andrews http://tom.home.cs.st-andrews.ac.uk twk@st-andrews.ac.uk Tom Kelsey ID5059-17-AUC
More informationDNA methylation in Uropathology
DNA methylation in Uropathology Clinical significance Rui Henrique, MD, PhD Director, Department of Pathology Difrector, Department of Education Senior Researcher, Cancer Biology and Epigenetics Group
More informationCirculating tumor cells/dna/etc for Radiation Oncologists
Circulating tumor cells/dna/etc for Radiation Oncologists Andrew Z. Wang, M.D. Associate Professor Director of Clinical and Translational Research Department of Radiation Oncology Carolina Center for Cancer
More informationNon-Profit Startup Paradigm Launches Cancer Panel Based on DNA, RNA Sequencing
Non-Profit Startup Paradigm Launches Cancer Panel Based on DNA, RNA Sequencing April 11, 2014 By Tony Fong Non-profit diagnostics outfit Paradigm last month joined a growing list of entrants in the clinical
More informationPrediction of Cancer Incidence and Mortality in Korea, 2013
pissn 1598-2998, eissn 256 Cancer Res Treat. 213;45(1):15-21 Special Article http://dx.doi.org/1.4143/crt.213.45.1.15 Open Access Prediction of Cancer Incidence and Mortality in Korea, 213 Kyu-Won Jung,
More informationNGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation
NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation Michael R. Rossi, PhD, FACMG Assistant Professor Division of Cancer Biology, Department of Radiation Oncology Department
More informationPatients Driving Progress
Patients Driving Progress Ellen V Sigal, PhD WIN Symposium 2018 June 25, 2018 Paris, France Nothing to disclose The Evolution of Patient Advocacy The Agnew Clinic, Thomas Eakins (1899) Partial mastectomy
More information38 Int'l Conf. Bioinformatics and Computational Biology BIOCOMP'16
38 Int'l Conf. Bioinformatics and Computational Biology BIOCOMP'16 PGAR: ASD Candidate Gene Prioritization System Using Expression Patterns Steven Cogill and Liangjiang Wang Department of Genetics and
More information